| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CLDX | Common Stock | Options Exercise | $311,400 | +30,000 | +331% | $10.38 | 39,074 | 14 Jun 2024 | Direct | |
| transaction | CLDX | Common Stock | Sale | $1,045,962 | -30,000 | -77% | $34.87 | 9,074 | 14 Jun 2024 | Direct | F1 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CLDX | Incentive Stock Option (Right to Buy) | Options Exercise | $0 | -30,000 | -39% | $0.000000 | 46,500 | 14 Jun 2024 | Common Stock | 30,000 | $10.38 | Direct | F2 |
| Id | Content |
|---|---|
| F1 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.51 to $35.39 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. |
| F2 | As of June 18, 2024, the option is fully vested. |